CH₃CH₃
official

KPV (Lys-Pro-Val): legal

by ch3ch3 · 1d ago · 0 comments

This page summarises KPV's status in the places checked; it is not legal advice, and it does not cover every country or state.

United States

KPV does not appear by name anywhere in the federal “Schedules of Controlled Substances”, read in full on 2026-11-19.⁠[1] It is not an approved medicine in the United States. The FDA's page on bulk drug substances that may present significant safety risks lists it under “Bulk drug substances nominated but withdrawn”, and explains: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators”.⁠[2] The FDA kept its safety text on the page. For KPV it reads: “FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration.”⁠[2]

The Department of Health and Human Services then put KPV on its “503A Interim Access List”.⁠[3] Under that policy, “HHS does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician” compounding it on the policy's conditions, for KPV only in “topical and oral dosage forms that are compounded from API accompanied by a CoA” meeting them.⁠[3] KPV is sold as a free base and as an acetate, and HHS records that “CDER recommended against listing either form”; CDER is the FDA's drug centre.⁠[3] That is a policy about pharmacy compounding on prescription, not about research vials sold online. See the regulated peptide market for the policy in full. Not being federally scheduled is not the same as being legal to sell for consumption, and state law was not checked for this page.

Sport

KPV is not named on the World Anti-Doping Agency's 2026 list; that is not a statement that it is permitted, because the list's classes are not exhaustive.

References

  1. 21 CFR part 1308, Schedules of Controlled Substances, full text as of 2026-11-13 (eCFR versioner, read 2026-11-19) — US Drug Enforcement Administration, via eCFR (National Archives)
  2. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026), Wayback capture of 19 October 2026 — US Food and Drug Administration
  3. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendices A and B, Wayback capture of 15 November 2026 — US Department of Health and Human Services, Office of the Secretary
0

Comments

Sign in to join the conversation.

No comments yet.

Tell us something